Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma

Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma

PurposeType 2 diabetes mellitus (T2DM) is among the risk factors for the occurrence and development of cancer. Metformin is a potential anticancer drug. Epidermal growth factor receptor (EGFR) plays an important role in the progression of oral squamous cell carcinoma(OSCC), but the relationship betw...

Full description

Bibliographic Details
Main Authors: Wei-Ming Wang, Si-Si Yang, Shu-Hui Shao, Huan-Quan Nie, Jing Zhang, Tong Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Endocrinology
Subjects:
type 2 diabetes mellitus
EGFR
OSCC
metformin
blood glucose
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.828608/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.828608/full

Similar Items